Literature DB >> 31368078

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

D Isla1, J de Castro2, R García-Campelo3, P Lianes4, E Felip5, P Garrido6, L Paz-Ares7, J M Trigo8.   

Abstract

PURPOSE: Immunotherapy-based approaches are standard first-line treatments for advanced/metastatic lung cancer or for chemoradiotherapy consolidation in locally advanced disease. Uncertainty on how to treat patients at disease progression prompted us to develop a consensus document on post-immunotherapy options in Spain for patients with advanced wild-type lung adenocarcinoma.
METHODS: After extensive literature review, a 5-member scientific committee generated 33 statements in 4 domains: general aspects (n = 4); post-durvalumab in locally advanced disease (n = 6); post-first-line immunotherapy ± chemotherapy in advanced/metastatic disease (n = 11); and post-first-line platinum-based chemotherapy in advanced/metastatic disease (n = 12). A panel of 26 lung cancer experts completed 2 Delphi iterations through an online platform rating their degree of agreement/disagreement (first-round scale 1-5 and second-round scale 1-4, 1 = strongly disagree, 4/5 = strongly agree) for each statement. Second-round consensus: ≥ 70% of responses were in categories 1/2 (disagreement) or 3/4 (agreement).
RESULTS: Consensus was reached for 2/33 statements in the first Delphi round and in 29/31 statements in the second round. Important variables informing treatment at disease progression with an immunotherapy-based treatment include: disease aggressiveness, previous treatment, accumulated toxicity, progression-free interval, PD-L1 expression, and tumour mutational burden. A platinum-based chemotherapy should follow a first-line immunotherapy treatment without chemotherapy. Treatment with docetaxel + nintedanib may be appropriate post-durvalumab in refractory patients or following progression to first-line chemotherapy + immunotherapy, or second-line chemotherapy after first-line immunotherapy, or first-line chemotherapy in some patients with low/negative PD-L1 expression, or second-line immunotherapy after first-line chemotherapy.
CONCLUSIONS: To support decision making following progression to immunotherapy-based treatment in patients with advanced wild-type lung adenocarcinoma, a consensus document has been developed.

Entities:  

Keywords:  Accumulated toxicity; Chemotherapy; Delphi consensus; Disease aggressiveness; Immunotherapy; Lung adenocarcinoma; Nintedanib; PD-L1 expression; Prior treatment; Progression-free interval; Treatment decisions; Tumour mutational burden

Mesh:

Substances:

Year:  2019        PMID: 31368078     DOI: 10.1007/s12094-019-02191-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  38 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  D Planchard; S Popat; K Kerr; S Novello; E F Smit; C Faivre-Finn; T S Mok; M Reck; P E Van Schil; M D Hellmann; S Peters
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

3.  Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Authors:  S Peters; U Dafni; M Boyer; D De Ruysscher; C Faivre-Finn; E Felip; P Garrido; N Girard; M Guckenberger; J Haanen; C Le Pechoux; F Mornex; M Ozsahin; L Paz-Ares; D Planchard; D Raben; S Ramalingam; M Reck; E Smit; R Stahel; A Stenzinger; C Swanton; S Vallone; M C Garassino
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

4.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

5.  Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.

Authors:  J Corral; M Majem; D Rodríguez-Abreu; E Carcereny; Á A Cortes; M Llorente; J M López Picazo; Y García; M Domine; M P López Criado
Journal:  Clin Transl Oncol       Date:  2019-02-15       Impact factor: 3.405

6.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

7.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors:  Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal:  Lancet       Date:  2014-06-02       Impact factor: 79.321

8.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Authors:  Louis Fehrenbacher; Alexander Spira; Marcus Ballinger; Marcin Kowanetz; Johan Vansteenkiste; Julien Mazieres; Keunchil Park; David Smith; Angel Artal-Cortes; Conrad Lewanski; Fadi Braiteh; Daniel Waterkamp; Pei He; Wei Zou; Daniel S Chen; Jing Yi; Alan Sandler; Achim Rittmeyer
Journal:  Lancet       Date:  2016-03-10       Impact factor: 79.321

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study.

Authors:  Martin Reck; Anders Mellemgaard; Silvia Novello; Pieter E Postmus; Birgit Gaschler-Markefski; Rolf Kaiser; Hannes Buchner
Journal:  Onco Targets Ther       Date:  2018-08-06       Impact factor: 4.147

View more
  5 in total

1.  Establishment of a Prognostic Model of Lung Adenocarcinoma Based on Tumor Heterogeneity.

Authors:  Pengdou Zheng; Huojun Zhang; Weiling Jiang; Lingling Wang; Lu Liu; Yuhao Zhou; Ling Zhou; Huiguo Liu
Journal:  Front Mol Biosci       Date:  2022-04-11

2.  Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors.

Authors:  Savreet Bains; Anu Kalsekar; Katayoun I Amiri; Jared Weiss
Journal:  JTO Clin Res Rep       Date:  2022-01-01

3.  Transmembrane p24 trafficking protein 2 regulates inflammation through the TLR4/NF-κB signaling pathway in lung adenocarcinoma.

Authors:  Longhua Feng; Pengjiang Cheng; Zhengyun Feng; Xiaoyu Zhang
Journal:  World J Surg Oncol       Date:  2022-02-08       Impact factor: 2.754

4.  Circular RNA-microRNA-mRNA network identified circ_0007618 and circ_0029426 as new valuable biomarkers for lung adenocarcinoma.

Authors:  Qiang Zhang; Yungang Sun; Chao Wang; Feng Shao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement.

Authors:  Gennady Bratslavsky; Neil Mendhiratta; Michael Daneshvar; James Brugarolas; Mark W Ball; Adam Metwalli; Katherine L Nathanson; Phillip M Pierorazio; Ronald S Boris; Eric A Singer; Maria I Carlo; Mary B Daly; Elizabeth P Henske; Colette Hyatt; Lindsay Middleton; Gloria Morris; Anhyo Jeong; Vivek Narayan; W Kimryn Rathmell; Ulka Vaishampayan; Bruce H Lee; Dena Battle; Michael J Hall; Khaled Hafez; Michael A S Jewett; Christina Karamboulas; Sumanta K Pal; A Ari Hakimi; Alexander Kutikov; Othon Iliopoulos; W Marston Linehan; Eric Jonasch; Ramaprasad Srinivasan; Brian Shuch
Journal:  Cancer       Date:  2021-08-03       Impact factor: 6.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.